Cybin Future Growth
Future criteria checks 0/6
Cybin is forecast to grow earnings and revenue by 56% and 64.4% per annum respectively. EPS is expected to grow by 60.4% per annum. Return on equity is forecast to be -6.4% in 3 years.
Key information
56.0%
Earnings growth rate
60.39%
EPS growth rate
| Pharmaceuticals earnings growth | 14.9% |
| Revenue growth rate | 64.4% |
| Future return on equity | -6.40% |
| Analyst coverage | Good |
| Last updated | 09 Jul 2026 |
Recent future growth updates
Recent updates
Helus Pharma: APPROACHing Inflection: Pivotal Readout Sets Up Asymmetric Upside
Summary I initiate coverage of Helus Pharma with a speculative Buy, citing an attractive high-risk/high-reward setup ahead of the pivotal Phase 3 APPROACH readout in Q4 2026. HELP’s lead asset HLP003, an oral deuterated psilocin analog for adjunctive MDD, shows compelling Phase 2 efficacy, FDA Breakthrough Therapy Designation, and a differentiated clinical profile. Current valuation (~$269M EV, ~$207M pro forma cash) under-credits the probability-weighted value of HLP003, with a risk-adjusted implied EV of ~$1.5B if Phase 3 succeeds. Risks include functional unblinding, commercial launch hurdles, and potential dilution, but cash runway appears sufficient for near-term catalysts and positive data could drive a material re-rating. Read the full article on Seeking Alpha
HELP: Sector Depression Trial Milestones Will Shape This Psychedelic Undervaluation View
Analysts have reduced their price target for Cybin to reflect a revised fair value estimate of about $70.05, citing updated views on long term revenue potential, profit margins, and an adjusted future P/E outlook informed by recent psychedelic sector research on comparable late stage drug developers. Analyst Commentary Recent sector research on late stage psychedelic drug developers is shaping how bullish analysts think about Cybin, especially when they compare it with peers working on deuterated psilocin and similar compounds.
HELP: Policy Momentum On PTSD Treatments Will Drive Future Psychedelic Therapy Demand
Analysts have lowered their Cybin price targets to around $7.78 from about $22.14, citing updated assumptions that include a somewhat higher discount rate, slightly softer long term profit margins, and a reduced but still very large future P/E multiple, partly offset by higher projected revenue growth. What’s in the News for Cybin Cybin completed a follow on equity offering of approximately $50.0 million, issuing 10,309,280 common shares at a price of $4.85 per share, with a stated discount of $0.291 per security.We Think Cybin (NASDAQ:HELP) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Psychedelic Therapy Trials Will Face Cash Strain Yet Could Unlock Long Term Upside
Catalysts About Cybin Cybin is a clinical stage biopharmaceutical company developing psychedelic based therapies for major depressive disorder and generalized anxiety disorder. What are the underlying business or industry changes driving this perspective?Late Stage Psychedelic Therapies And Clinic Partnerships Will Reshape Treatment For Depression And Anxiety
Catalysts About Cybin Cybin is a clinical stage biopharmaceutical company developing psychedelic based therapies for major depressive disorder and generalized anxiety disorder. What are the underlying business or industry changes driving this perspective?
Interventional Psychiatry And Clinic Partnerships Will Support Long Term Psychedelic Treatment Adoption
Catalysts About Cybin Cybin is a clinical stage company developing psychedelic based treatments for major depressive disorder and generalized anxiety disorder. What are the underlying business or industry changes driving this perspective?Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2029 | 204 | -83 | -81 | -117 | 5 |
| 3/31/2028 | 2 | -188 | -172 | -173 | 5 |
| 3/31/2027 | N/A | -183 | -198 | -178 | 6 |
| 3/31/2026 | N/A | -148 | -135 | -133 | N/A |
| 12/31/2025 | N/A | -123 | -114 | -112 | N/A |
| 9/30/2025 | N/A | -87 | -99 | -98 | N/A |
| 6/30/2025 | N/A | -97 | -85 | -84 | N/A |
| 3/31/2025 | N/A | -82 | -74 | -72 | N/A |
| 12/31/2024 | N/A | -75 | -73 | -72 | N/A |
| 9/30/2024 | N/A | -91 | -74 | -74 | N/A |
| 6/30/2024 | N/A | -57 | -63 | -62 | N/A |
| 3/31/2024 | N/A | -58 | -51 | -51 | N/A |
| 12/31/2023 | N/A | -53 | -45 | -45 | N/A |
| 9/30/2023 | N/A | -37 | -33 | -32 | N/A |
| 6/30/2023 | N/A | -37 | -38 | -35 | N/A |
| 3/31/2023 | N/A | -35 | -38 | -35 | N/A |
| 12/31/2022 | N/A | -38 | -37 | -34 | N/A |
| 9/30/2022 | N/A | -42 | -37 | -35 | N/A |
| 6/30/2022 | N/A | -51 | -37 | -37 | N/A |
| 3/31/2022 | N/A | -54 | -37 | -36 | N/A |
| 12/31/2021 | N/A | -50 | -34 | -33 | N/A |
| 9/30/2021 | N/A | -45 | -30 | -30 | N/A |
| 6/30/2021 | N/A | -34 | -22 | -21 | N/A |
| 3/31/2021 | 1 | -26 | -15 | -15 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HELP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HELP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HELP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HELP is forecast to have no revenue next year.
High Growth Revenue: HELP is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HELP is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/16 17:45 |
| End of Day Share Price | 2026/07/16 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cybin Inc. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| David Martin | Bloom Burton & Co. |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |